Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Eltrombopag (Revolade®) is recommended as an option for use within NHS Wales for the treatment of patients aged 1 year to < 18 years with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | eltrombopag (Revolade®) | ||
| Formulation | 25 mg, 50 mg film-coated tablet; 25 mg powder for oral suspension | ||
| Reference number | 2692 | ||
| Indication | Treatment of patients aged 1 year to < 18 years with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2916 | ||
| NMG meeting date | 07/09/2016 | ||
| AWMSG meeting date | 12/10/2016 | ||
| Ratification by Welsh Government | 20/10/2016 | ||
| Date of issue | 21/10/2016 | ||
| Date of last review | August 2020 | ||
| Commercial arrangement | PAS | ||